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R812Cancer: miRNA Addiction —
Depending On Life’s Little ThingsMicroRNAs (miRNAs) pleiotropically modulate gene expression in all cell types.
Many miRNAs are overexpressed in tumors, and recent findings suggest that
tumors can be ‘addicted’ to miRNA overexpression, yielding a possible
therapeutic opportunity.David Dornan and Jeff Settleman
MicroRNAs (miRNAs) are small non-
coding RNAs that function primarily
to negatively regulate mRNA stability
of protein-coding genes [1].
This regulation is achieved by
the binding of a miRNA to the 30
untranslated region (UTR) of
a protein-coding mRNA that
harbors a ‘seed’ sequence, typically
complementary to 2–8 nucleotides
from the 50 end of the miRNA, and the
promotion of mRNA degradation.
miRNAs have been implicated in
a wide range of developmental and
physiological processes, and recently
accumulating evidence indicates that
miRNAs may play significant roles in
a variety of human tumors [2]. Thus,
miRNA expression profiles have been
associated with particular cancer
types, where they may be useful as
diagnostic and/or prognostic
classifiers [3], and some miRNAs
have been reported to demonstrate
oncogenic and tumor suppressor
properties [4]. Consistent with
functional roles in tumorigenesis, some
miRNAs have been identified that
regulate cancer-associated processes,
including metastasis, invasion, and
self-renewal [5,6].
A recent report in Nature by Medina
et al. [7] described findings that
highlight another aspect of miRNAs
in cancer — ‘oncomiR addiction’.
The concept of ‘oncogene addiction’,
which refers to the acquired
dependency of tumor cells on
a single oncoprotein or oncogenic
pathway for sustained viability or
proliferative potential [8], has gained
considerable attention in recent years,
due in large part to the therapeutic
opportunity that this phenomenon
presents [9]. Medina and colleagues [7]
have employed a genetically
engineered mouse model to
demonstrate that tumors can similarly
become addicted to the expression
of a miRNA — in this case, miR-21.
This miRNA has previously beenimplicated in a variety of human
cancers, by virtue of its frequent
overexpression, and may also be
associated with poor prognosis in
some settings [10–12].
Several previous reports have
demonstrated that particular
miRNAs, including miR-21, may also
be required to maintain tumor cell
survival, as revealed in cell culture and
xenograft models [10,13]. Medina et al.
[7] have taken this a step further
by demonstrating an apparent
dependency on sustained miR-21
expression in a genetically engineered
mouse model. MiR-155 is the only
other miRNA that has been shown
thus far to promote tumorigenesis
when overexpressed in mice.
Those animals developed acute
lymphoblastic leukemia and
high-grade lymphomas; however,
it was not determined whether the
resulting tumors remain dependent
on sustained miR-155 expression [14].
In the study by Medina et al. [7] the
investigators established a mouse
model in which miR-21 expression
could be inducibly switched on or off.
Transgenic animals demonstrated
miR-21 overexpression in the brain,
thymus, spleen, and the hematopoietic
cell compartment. Following two
months of induced miR-21
overexpression, the mice developed
clinical signs of haematological
malignancies, including enlarged
lymph nodes and spleen. The specific
pathology associated with miR-21
overexpression was pre-B-cell
lymphoma, indicating that enforced
miR-21 expression is sufficient to
promote tumor initiation. Then, to
determine whether sustained miR-21
expression was required to maintain
malignancy, miR-21 expression was
switched off. In a strikingly short period
of time — less than a week — all of
the tumor-bearing mice recovered
from the observed clinical signs of
haematological malignancies. More
importantly, these animals all displayed
rapid tumor regression upon miR-21suppression, and a survival rate of
100% was observed when animals
were examined after more than
3 months from the time that miR-21
expression had been switched off.
The observed rapid kinetics of tumor
regression prompted the authors to
establish whether miR-21 suppression
promoted apoptosis. Notably, miR-21
has been previously shown to play an
anti-apoptotic role by modulating the
expression of genes such asBCL2 [10],
PTEN [15], and PDCD4 [16]. Indeed,
suppression of miR-21 resulted in
a pronounced upregulation of early
and late apoptotic markers. Moreover,
co-administration of a general caspase
inhibitor (Z-VAD-FMK) dampened this
response and partially ‘rescued’ tumor
regression, thereby directly implicating
apoptotic tumor cell death in the
response to miR-21 suppression.
The investigators ruled out the formal
possibility that de-differentiation
of tumor cells could be a mechanism
for the observed regression.
The oncogene addiction model is
probablymost significant in the context
of oncoprotein-targeted cancer
therapy. Among the most compelling
examples to support the clinical
significance of this model are
BCR–ABL addiction in chronic
myelogenous leukemia, EGFR
addiction in non-small cell lung cancer,
and ERBB2/HER2 addiction in breast
cancer — settings in which inhibition of
these oncogenic kinases is tightly
associated with clinical benefit [17,18].
With the more recent discovery of
a plethora of non-coding RNAs within
the human genome, including miRNAs,
there has been considerable interest in
determining whether these regulatory
RNAs could similarly serve as
therapeutic targets. Previous work has
also reported examples of pre-clinical
models in which inhibition of particular
oncomiRs resulted in robust cell killing
in vitro as well as inhibition of tumor
growth in xenograft models [10,13].
Such findings similarly support the
concept of oncomiR addiction and, in
fact, it was in one of those reports that
the term oncomiR addiction was first
proposed [13].
The findings from Medina et al. [7]
suggest that certain miRNAs, such
as miR-21, may constitute important
targets for therapeutic intervention in
human cancer. However, a variety of
technical and logistical challenges
must first be overcome to enable the
Dispatch
R813effective delivery of a miRNA-targeted
agent to tumor cells in vivo. Moreover,
it would most likely be necessary to
identify, prior to treatment with such an
agent, those tumors demonstrating
a strict dependency onmiR-21. Despite
the relatively broad overexpression of
miR-21 in various cancers [11], it seems
unlikely that all, or even most, tumors
that overexpress miR-21 would
demonstrate significant regression
following miR-21 inactivation.
Therefore, a more extensive analysis of
miR-21 addiction in a large panel of
cancer cell lines and mouse tumor
models would be of considerable value
in initially assessing the scope of
miR-21 dependency across the cancer
landscape. Such an analysis should
also provide some perspective on the
therapeutic index one would anticipate
in the context of therapeutic targeting
of miR-21. In this regard, it will also be
of interest to determine the potential
consequences of miR-21 disruption
in normal tissues, which has not been
reported thus far.
In light of the technical challenges
associated with the direct targeting of
miR-21, it may also be useful to identify
the critical gene target(s) of miR-21 that
mediate its oncogenic function, as one
or more of these may constitute more
pharmacologically tractable targets.
Given that miR-21 has been shown
to have multiple putative gene targets
[10,15,16], functional validation studies
will be required to address this
potentially complex issue. However,
since miRNAs generally promote the
repression of gene expression, and it
is therefore not surprising to find that
many of the established targets of
oncomiRs are in fact tumor suppressor
genes [15,19,20], it may prove difficult
to identify ‘druggable’ oncomiR-
regulated targets.
In sum, these new findings by
Medina et al. [7] add yet another
dimension to the oncogene addiction
phenomenon. The possibility of
targeting specific miRNAs required to
maintain tumor cell survival as
a therapeutic strategy is provocative,
but is certainly a challenging prospect
from a drug development and
delivery standpoint. Future efforts will
undoubtedly be required to establish
the broader significance of oncomiR
addiction, to identify the most relevant
miRNAs in specific tumor indications,
to establish the mechanisms by which
miRNA overepression contributes to
the maintenance of tumor cell viability,and to develop therapeutic strategies
to inactivate specific miRNAs. And
these are just the little things.
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Involving Parietal Cortex
Our brain is constantly interpreting ambiguous sensory input to deliver a stable
perceptual representation of the environment. Two new studies suggest that
superior parietal cortex plays a causal role in resolving perceptual ambiguity.
Ironically, their results are somewhat ambiguous as to what that role might be.Colin W.G. Clifford
It is easy to underestimate the
complexity of the visual processing
required to make sense of the worldaround us. It was arguably only when
the pioneers of artificial intelligence
started trying to program computers
to see that the true magnitude of
the task of vision became widely
